TNF inhibition for ophthalmic indications: Current status and outlook

BioDrugs

Volumn 27, Issue 4, 2013, Pages 347-357

  Rifkin, Lana M ^a   Birnbaum, Andrea D ^a   Goldstein, Debra A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; REMICADE CENTOCOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

COCHRANE LIBRARY; CONGESTIVE HEART FAILURE; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EYE INFLAMMATION; HUMAN; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; LUNG EMBOLISM; LUPUS LIKE SYNDROME; LYMPHOMA; MEDLINE; OPTIC NEURITIS; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; RETINA VASCULITIS; REVIEW; SCLERITIS; SIDE EFFECT; UVEITIS; VITREOUS HEMORRHAGE;

EID: 84880790909     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0022-9     Document Type: Review

References (79)

1. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-16.
2. Foster CS, Vitale AT. Diagnosis and treatment of uveitis. 1st ed. Philadelphia: WB Saunders; 2002. p. 17-23.
3. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: The Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491-500.
4. Chiang YP, Bassi LJ, Javitt JC. Federal budgetary costs of blindness. Milbank Q. 1992;70(2):319-40.
5. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14(5-6):303-8.
6. Birnbaum AD, Little DM, Tessler HH, et al. Etiologies of chronic anterior uveitis at a tertiary referral center over 35 years. Ocul Immunol Inflamm. 2011;19(1):19-25.
7. Okharavi N, Odufuwa B, McCluskey P, et al. Scleritis. Surv Ophthalmol. 2005;50(4):351-63.
8. Akpek EK, Thorne JE, Qazi FA, et al. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004;111(3):501-6.
9. Saintz de la Maza MS, Molina N, Gonzalez-Gonzalez LA, et al. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology. 2012;119(1):43-50.
10. Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology. 1994;101(2):389-96.
11. Pfeffer K. Biologic functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003;14(3-4):185-91.
12. Gullick NJ, Scott DL. Drug therapies of inflammatory arthritis. Clin Med. 2012;12(4):357-63.
13. Gregory AC, Kempen JH, Daniel E, Kaçmaz RO, et al; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive therapy for eye diseases study. Ophthalmology. 2012. doi: 10.1016/j.ophtha.2012.07.052.
14. Scott DL. Etanercept in arthritis. Int J Clin Pract. 2005;59(1):114-8.
15. Nestorov J. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34(5 Suppl 1):12-8.
16. Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000;27(4):841-50.
17. Martel JN, Esterberg E, Nagpal A, et al. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;20(1):18-26.
18. Bourne T, Fossati G, Nesbitt A. A PEGylated Fab′ fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. Biodrugs. 2008;22(5):331-7.
19. Tlucek PS, Stone DU. Certolizumab pegol-therapy for rheumatoid arthritis associated scleritis. Cornea. 2012;31(1):90-1.
20. Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor A. MAbs. 2010;2(4) [Epub ahead of print].
21. Cordero-Coma M, Salom D, Diaz-Llopis M, et al. Golimumab for uveitis. Ophthalmology. 2012;118(9):1892.e3-4.
22. Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion versus corticosteroids for acute panuveitis attacks in Behcet's disease: a comparative four-week study. Rheumatology. 2011;50(3):593-7.
23. Greenberg SB. Infections in the immunocompromised rheumatologic patient. Crit Care Clin. 2002;18:931-56.
24. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology. 2012;51(Suppl 6):vi37-43.
25. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098-104.
26. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol. 2008;35:421-4.
27. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008;35:1944-9.
28. Van Dartel SA, Fransen J, Kierit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2012 [Epub ahead of print].
29. Solomon AJ, Spain RI, Kruer MC, et al. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler. 2011;17(12):1472-87.
30. Li SY, Birnbaum AD, Goldstein DA. Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immuno Inflamm. 2010;18(6):475-81.
31. Chung ES, Packer M, Lo KH, Fasanmade AA, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-40.
32. Debandt M, VIttecog O, Descamps V, Le Loet X X, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol. 2003;22(1):56-61.
33. Lamirau T, Cezardo JP, Dabadie A, Goulet D. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 2004;10(6):745-50.
34. FDA. 2008. Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as remicade, Enbrel, humira, and cimzia). http://www.fda.gove/drugs/drugsafety/ postmarketdrugesafetyinformationforpatientsandproviders/ drugsafetyinformationforhealthcareprofessionals/UCM070725.
35. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children; forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62:2517-24.
36. Lehman TJ. Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis? Arthritis Rheum. 2010;62:2183-4.
37. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903-12.
38. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009;127(6):819-22.
39. Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125(7):895-900.
40. Lopez Gonzalez R, Loza E, Jover JA, et al. Treatment for refractory posterior uveitis with infliximab: a 7 year follow up study. Scand J Rheumatol. 2009;38(1):58-62.
41. Turan B, Pfister K, Diener PA, et al. Soluble tumor necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's disease. Scand J Rheumatol. 2008;37(2):135-41.
42. Tabbara KF, Al-Hemidal A. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146(6):845-50.
43. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94:284-8.
44. Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behçet's disease receiving infliximab treatment. Br J Ophthalmol. 2011;95:205-8.
45. Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Rheumatol Int. 2011;31(1):33-7.
46. Keino H, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy. Br J Ophthalmol. 2011;95(9):1245-50.
47. Iwata D, Namba K, Mizuuchi K, et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behcet's disease with infliximab. Graefes Arch Clin Exp Ophthalmol. 2012;250(7):1081-7.
48. Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: a retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144(6):844-9.
49. Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860-4.
50. Simonini G, Zannin ME, Caputo R, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology. 2008;47(10):1510-4.
51. Milman N, Andersen CB, Hansen A, et al. Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. APMIS. 2006;114(12):912-9.
52. Gupta SR, Phan IT, Suhler EB. Successful treatment of refractory sympathetic ophthalmia in a child with infliximab. Arch Ophthalmol. 2011;129(2):250-2.
53. Khalifa YM, Bailony MR, Acharya NR. Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab. Ocul Immunol Inflamm. 2010;18(3):218-22.
54. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111(2):352-6.
55. Sen HN, Sangave A, Hammel K, et al. Infliximab for the treatment of active scleritis. Can J Ophthalmol. 2009;44(3):e9-12.
56. Doctor P, Sultan A, Syed S, et al. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol. 2010;94:579-83.
57. Díaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab treatment for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24:351-61.
58. Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575-81.
59. Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicenter, open-label, prospective trial. Br J Ophthalmol. [Published Online 2/2013]. doi: 10.1136/bjophthalmol-2012-302292.
60. Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye. 2009;23(9):1868-70.
61. Olivieri I, Leccese P, D'Angelo S, et al. Efficacy of adalimumab in patients with Behcet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29(4 Supp1 67):S54-7.
62. Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. 2008;47(3):339-44.
63. Simonini G, Tiddio A, Cattalini M, et al. Prevention of flare recurrences in childhood refractory chronic uveitis: an open label comparative study of adalimumab versus infliximab. Arthritis Care Res. 2011;63:612-8.
64. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460-8.
65. Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int. 2011;31(2):243-5.
66. Leccese P, Latanza L, D'Angelo S, et al. Efficacy of switching to adalimumab in a patient with refractory uveitis in Behçet's disease to infliximab. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S93.
67. Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol. 2010;29(5):559-61.
68. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44(6):1411-5.
69. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121(4):437-40.
70. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18-23.
71. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113(12):2317-23.
72. Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503-10.
73. Gaujoux-Viala C, Giampietro C, Gaujoux T, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39(2):233-9.
74. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Care Res. 2001;45:252-7.
75. Farvardin M, Afarid M, Mehryar M, et al. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina. 2010;30:1530-5.
76. Wu L, Hernandez-Bogantes E, Roca JA, et al. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina. 2011;31(2):298-303.
77. Giganti M, Beer PM, Lemanski N, et al. Adverse events after intravitreal infliximab (Remicade). Retina. 2010;30(1):71-80.
78. Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010;117(8):1612-6.
79. Markomichelakis N, Delicha E, Masselos S, et al. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol. 2012;154:534-41.